Project Grant HT94252311026
Award Date 9/30/23
Completion Date 9/29/26
Dollars Obligated $567K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The University of Texas MD Anderson Cancer Center received a $1,619,997 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on targeting ferroptosis and mitochondrial pathways in acute myeloid leukemia. The 3-year award, which commenced on September 1, 2023, will support preclinical studies, clinical trials, and other research activities at the cancer center's facilities in Houston, Texas. As a component...
- This federal Project Grant award of $566,998.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research targeting acute myeloid leukemia (AML) using a CD123-directed NK-cell engager and NK cell immune therapy, as well as harnessing the apoptotic machinery through BCL-2 inhibition. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period from September 30, 2024 to...
- The Department of the Army Medical Command awarded a $4,275,962 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program to The University of Texas M.D. Anderson Cancer Center (MD Anderson) on September 15, 2024. The grant supports a 4-year research initiative to develop CD79B-targeting CAR T-cell therapy for B-cell lymphomas. MD Anderson, a prominent academic cancer research and treatment institution, will leverage its expertise in immunotherapy,...
- The University of Texas MD Anderson Cancer Center was awarded a $1,306,991.00 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "ORGANOID-BASED MODELING AND THERAPEUTIC TARGETING OF TP53-MUTATED ACUTE MYELOID LEUKEMIA". The award has a performance period from August 1, 2025 to July 31, 2029 and will support advanced biomedical research aimed at transforming healthcare for military service members,...
- This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,127,579.00 to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct a Phase 1b/2a clinical trial evaluating the anti-IL1RAP antibody nadunolimab in patients with myelodysplastic syndrome and acute myelogenous leukemia. The award commenced on September 30, 2023 and is scheduled for completion by September 29,...
- The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
- This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
- The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, received a $486,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The 3-year grant, with a start date of September 30, 2023, supports research targeting the PRMT5 protein in melanoma with MTAP gene loss. The funding will enable preclinical studies, including evaluating novel treatments, to advance the understanding and...
- This Project Grant award for $536,186.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct research on APOBEC3A and its role in tumor evolution and intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC). The award will fund this research project over a 3-year period from Sep 30, 2023 to Sep 29, 2026. As...
- The U.S. Defense Health Agency has awarded a $7,001,734 Project Grant to The University of Texas MD Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The grant, which runs from August 15, 2024 to August 14, 2028, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to drive innovative cancer research and explore new approaches to prevention, diagnosis,...